$ALHC

KONOWIECKI JOSEPH S sold $600K of ALHC

KONOWIECKI JOSEPH S (EVP, Corporate Affairs) sold 25,000 shares of Alignment Healthcare, Inc. (ALHC) at $24.00 ($0.60M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KONOWIECKI JOSEPH S
Published Jul 1, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The newest fact is the specific sale: 25,000 shares at $24.00/share totaling $600,000, executed on 2026-07-01 under a 10b5-1 plan.

02

Market read

This is a routine insider-sale datapoint; it may marginally influence sentiment but lacks fundamental catalysts in the text.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, contracts, or operating metrics, the filing is unlikely to drive fundamentals.

Relevance 4/10Novelty 5/10Timing: filed after-hours on 2026-07-01 (SEC EDGAR timestamp)

Background

The article is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Form 4 shows Alignment Healthcare EVP Joseph S Konowiecki sold 25,000 shares for $600,000 on 2026-07-01 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a primary-source Form 4, but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No broader sector datapoint; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • KONOWIECKI JOSEPH S

    EVP, Corporate Affairs; reported open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Why Alignment Healthcare (ALHC) Stock Is Up Today

Alignment Healthcare (ALHC) shares rose 8.6% after its subsidiary announced a new Medicare Advantage plan in Los Angeles and Orange counties. Analyst Ryan Langston lowered his price target to $12 but maintained a Buy rating, citing inpatient utilization pressure. The stock had fallen 13.4% the previous day due to a downgrade and regulatory concerns.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$ALHCHigh

ALHC Stock Slides As Legal, Cost, And Rating Pressures Mount

Alignment Healthcare Inc. (ALHC) stock fell 14.75% on October 9, 2026, amid concerns over Medicare Advantage reimbursement pressures, legal issues, and cost challenges. The company reported $1.34B in revenue and $36.6M in net income for the latest quarter, but negative cash flow raised concerns. CMS's 2027 Star Ratings and a whistleblower's accounting allegations further pressured the stock, with Barclays cutting its price target to $10.